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"The stunted stature, the semi-bestial aspect, the 
blubber lips, retrousse nose, sunken at the root, 
the wide-open mouth, the lolling tongue, the small 
eyes, half closed with swollen lids, the solid, 
expressionless face, the squat figure, the muddy, 
dry skin, combine to make the picture of what has 
been well-termed the ‘pariah of nature'. 
Not the magic wand of Prospero or the brave kiss 
of the daughter of Hippocrates ever effected such 
a change as that which we are now enabled to make 
in these unfortunate victims..." 
Wi11iam Osier, M.D.: Internal Secretions; Considered 
in their Physiological, Pathological and Clinical Aspects. 
Sporadic Cretinism in America. Transactions of the 
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INTRODUCTION 
The recent suggestion that congenital hypothyroidism 
may occur as often as I in 6,000 deliveries has reawakened 
interest in the diagnosis and treatment of this disease (2,3,5). 
Even though congenital hypothyroidism may be identified during 
newborn screening programs, it is not clear whether thyroid 
hormone therapy, even when begun shortly after birth, will 
result in full attainment of intellectual potential (6,72). 
Consequently, there has been interest in the early diagnosis 
and treatment of hypothyroidism in utero (11-14,94). Chopra 
and Crandall (13) have suggested that 3,3',5triiodothyronine 
(reverse T^) levels in amniotic fluid may be a good measure 
of fetal thyroid function. Van Herle et al (16) have treated 
a fetus exposed to radioactive iodide with injections of 
thyroxine (T^) in utero. However, despite in utero thyroid 
hormone therapy, the patient was hypothyroid at birth. 
If maternal thyroid hormone were available to the 
fetus in adequate amounts, hypothyroidism in utero would not 
be a matter of concern. However, available evidence suggests 
that placental transfer of iodothyronines is minimal (26,27, 
56,64-68). The ability of compounds to cross the placenta 
depends on a number of factors including molecular weight, 
lipid solubility, and protein binding (41,42). Recently, 
Jorgensen and his coworkers (69,70) have synthesized 
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biologically active thyroid hormone analogues which are 
smaller molecules with increased lipid solubility and 
decreased binding to thyroxine-binding-globulin (TBG) in 
comparison to the iodothyronines. 
The current study was undertaken in an attempt 
to assess placental transmission of the thyroid hormone 
analogues and their thyromimetic activity in the 




Hypothyroidism can be detected at birth by measuring 
serum thyroxine (T^) and thyroid-stimulating hormone (TSII). 
Early clinical diagnosis \-7as difficult because hypothyroid 
infants typically appear euthyroid at birth (1). Recent pilot 
screening programs, using the radioimmunoassay for or TSH, 
have suggested that congenital hypothyroidism may occur in as 
often as 1 in 6,000 deliveries (2,3). This incidence surpasses 
that of phenylketonuria (PKU), which occurs with a national 
frequency of 1 in 14,300 (4), and is the subject of a national, 
screening program. 
The various methods of detection of hypothyroidism 
in the newborn include umbilical cord and capillary blood 
determinations of T^ and TSH either directly or with eluates 
of filter paper blood spots prepared from capillary blood (2,3). 
Determination of TSH level is the most discriminating test in 
the diagnosis of primary hypothyroidism. However, determining 
serum TSH is more expensive as a screening technique and, in 
addition, would fail to detect TBG abnormalities (2). A more 
satisfactory method might be to obtain cord blood for T^; if 
serum T^ is low, then TSH levels could be determined 
immediately. Follow-up time would also be shortened in 
obtaining serum for TSH that would.be necessary using the 
filter paper technique (5). 

-4- 
Whether the early diagnosis and postnatal 
treatment of the athyreotic newborn prevents residual brain 
damage is not clear. Klein, Meltzer, and Kenny (6) observed 
that thyroid hormone replacement in the human infant with 
congenital hypothyroidism improved mental retardation, if 
treatment was begun before three months of age. However, if 
the critical period of brain development begins prenatally 
in humans (7), early postnatal detection and treatment of 
congenital hypothyroidism may not completely prevent 
central nervous system (CNS) damage (72). More than half of 
fifty patients with congenital hypothyroidism had signs of 
cerebellar dysfunction such as ataxic gait, dysdiadochokinesis 
and clumsiness for variable periods of their life, despite 
being diagnosed and treated within the first three months of 
life (8). Smith, Blizzard and Wilkins (72) observed that the 
greater the extent of intrauterine hypothyroidism the worse 
the prognosis in severe cretins even though adequately 
treated by four months of age. In utero diagnosis and 
treatment of congenital hypothyroidism might allow for an 
improved prognosis of the disease. 
Previous studies have indicated that the fetal 
thyroid is capable of synthesizing iodothyroniries by ten 
weeks of gestation (9) with detectable fetal serum levels 
by the eleventh week (10). Thyroid hormone has also been 
found in amniotic fluid (11). But measurements of amniotic 

fluid thyroxine (T^) has not proven helpful in the diagnosis 
of fetal thyroid status (11-13). No correlation was found 
between amniotic fluid total free levels and either maternal 
or fetal serum TSIi concentrations; amniotic fluid levels 
probably reflects both maternal and fetal hormone (11,12). 
TSH and were undetectable in human amniotic fluid, although 
was easily measured in both maternal and fetal blood (11). 
Recently, Chopra and Crandall (13) have shown that 
it may be possible to diagnose fetal hypothyroidism early in 
pregnancy by measuring 3,3',5triiodothyronine (reverse T^) 
level in amniotic fluid. Reverse is a normal component 
of human serum and tliyroglobulin. Peripheral metabolism 
of T^, by the action of an a-ring deiodinase, is an 
important source of this iodothyronine (14,101). This 
hormone has little calorigenic activity (95), although it 
has been shown capable of exerting an anti-thyroxine effect (96). 
At 15 weeks of pregnancy, reverse concentration in amniotic 
fluid were found to be high and thought to be primarily of 
fetal origin as levels exceeded those in maternal serum (13). 
Although after the 30th week of gestation amniotic fluid 
reverse decreased, levels always exceeded maternal serum 
reverse concentration which remained essentially unchanged 
throughout pregnancy (13). Amniotic levels of and reverse 
parallel serum concentrations in the newborn and are distinct 
from maternal serum levels. In the fetus at term, serum 
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was found to be markedly subnormal while serum reverse was 
clearly elevated (14,15). Chopra (14) has also demonstrated 
decreased serum reverse concentrations in hypothyroidism 
while increased concentrations were found in hyperthyroidism. 
Presumably, the hypothyroid fetus would have low levels of 
amniotic fluid reverse in comparison to the euthyroid fetus. 
The measurement of reverse by amniocentesis, as early as 
15 weeks of gestation, may prove to be helpful in the diagnosis 
of congenital hypothyroidism in utero (13). 
The majority of cases of congenital hypothyroidism 
occur sporadically. However, clinical situations exist in 
which the liklihood of fetal hypothyroidism is high. Of 
particular note is the destruction of the fetal thyroid in 
the pregnant mother inadvertently exposed to radioiodine 
during the latter two-thirds of gestation (16,17,97). The 
developing fetal thyroid is capable of concentrating radioactive 
131 
iodine by the third month of gestation (17). I given to 
a mother near term reaches a tenfold greater concentration in 
the fetal thyroid than in the mother's gland (18). Asthmatic 
pregnant women treated with inorganic iodide can give birth 
to infants with large goiters (19,20). Most of these infants 
do well providing they escape death by asphyxiation due to 
tracheal obstruction (19). However, signs of hypothyroidism 
at birth may cause permanent damage in some of these infants, 
even if they become euthyroid rapidly (21). 
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The risk of fetal hypothyroidism or goiter is 
also present in fetuses of hyperthyroid pregnant women 
treated with anti-thyroid medication (28) . It is thought 
that goitrogenesis results from the increased secretion of 
fetal pituitary TSH in response to the decreased production 
of fetal thyroid hormone induced by the anti-thyroid drug 
which has crossed the placenta (28,29,39). The occurrence 
of fetal complications has not been found to be directly 
dose related. It is postulated that the effects of fetal 
exposure to an anti-thyroid drug may be genetically 
determined (22,23,27). Most of the children exposed to an 
anti-thyroid drug in utero with subsequent goiter formation 
have no lasting effects, although there have been isolated 
case reports of mental retardation occurring in such 
children (22). In a retrospective study of 30 women treated 
with propylthiouracil (PTU) during 41 pregnancies, five 
children were born with goiters. There was a question of 
mental retardation in a follow-up exam of one of the five 
goitrous newborns (22). Selenkow (24,25) advocates that 
thyroid hormone supplementation is important for pregnant 
women on anti-thyroid medication to prevent maternal 
hypothyroidism and protect the fetus from goiter. However, 
it is not at all clear that fetal hypothyroidism would be 
avoided; evidence suggests that transplacental passage of 
iodothyronines is minimal (22,26). It is not known why 
treatment of thyrotoxic mothers with anti-thyroid drugs 
pH 
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only infrequently results in the birth of hypothyroid 
or goitrous infants. There are two case reports of only one 
of each set of dizygotic twins born with a goiter as a result 
of maternal treatment with anti-thyroid medication during 
gestation (27). Serum TSH was elevated in both affected infants; 
diminished serum was found in one twin. This selective 
effect of anti-thyroid drugs may be due to genetic differences 
in metabolic clearance rates of the anti-thyroid compounds 
similar to that observed with other drugs, or perhaps, 
differences in the thyroidal uptake by the fetal gland of 
the anti-thyroid drugs may be responsible (27). 
Sporadic congenital hypothyroidism can be due to 
athyreosis secondary to an embryologic developmental defect 
of the thyroid gland (31,32). Rarely, neonatal athyreosis 
may have resulted from destruction of the thyroid gland by 
autoimmune diseases such as Hashimoto's thyroiditis (33-35). 
Inborn errors of thyroid hormonogenesis (36), or peripheral 
tissue resistance to the action of thyroid hormones (37,38) 
are other very uncommon causes of sporadic hypothyroidism. 
If amniotic fluid concentration of reverse T^ 
proves to correlate well with fetal thyroid status, amniocentesis 
would be of great diagnostic value. Initially, cases with a 
known increased risk of fetal thyroid dysfunction would 
probably be evaluated as amniocentesis does engender some 
risks (40). Pregnancies in which the fetus had been exposed 

-9- 
to radioiodine or in- which the mother had been treated 
with anti-thyroid therapy or potentially goitrogenic drugs 
would also be included. Amniocentesis might also prove to 
be very beneficial for the mother with a positive family 
history of inborn defects of thyroid hormone metabolism (40), 
Conflicting data exists about the extent to which 
the iodothyronines cross the placenta. Although some placental 
transfer of maternal thyroid hormone probably occurs during 
the last third of pregnancy in the rat (43-45), guinea pig (46- 
49,57), rabbit (50), sheep (51-53), monkey (54,55), and 
man (26,56), available evidence suggests that it is 
limited (30,54,57). 
In general, it is thought that placental transmission 
of drugs is based upon lipid solubility, ionic charge and 
concentration gradient of undissociated molecules, serum 
protein binding, and molecular size (41). Compounds with 
molecular weights of less than 500 tend to cross more easily, 
while those with a higher molecular weight cross with 
increasing difficulty. A high lipid/water solubility enhances 
placental transfer, and the non-ionized molecule is also more 
lipophilic. In addition, protein binding is very important 
as only unbound drugs are available for transfer (41,42). It 
is not clear which of the above factors or combination of 
factors dominates in placental transfer of iodothyronines. 
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The administration of a large dose of (200 yg/day) 
to pregnant rats will prevent the development of propylthiouracil 
(PTU) goiter in the fetus (58). These same observations have 
been made in. the guinea pig and rabbit (46,50). In all of 
these species, the placental transfer of labelled and is 
found to be limited (30,47-49). In the sheep, Fisher et al (53) 
shows marked base line fetal-maternal serum concentration 
gradients of T^, free T^, T^, and free . After fetal ovine 
thyroidectomy, there is rapid disappearance of and , 
and an increase in serum TSH (61-63). Reduction in fetal 
and production rates to 5-10% of normal values occurs (63). 
When the pregnant rhesus monkey is given in quantities 
increasing serum levels to 300%., fetal serum T, does not 
change and synthesis by the fetal thyroid gland is not 
inhibited (54). 
Human data is similar. Limited placental transfer 
of iodothyronines is observed at term. When the pregnant 
woman is given large quantities of (1500 -8000 yg) or 
(300 yg) at term or during labor, maternal-fetal hormone 
transfer is noted (26,64). Only about 1%. of the 8000 yg 
load reaches the fetus and the chronic 300 Pg/day of reduces 
the fetal serum levels minimally and inconsistently (65,66). 
In all species investigated, little or no hormone transverses 
the placenta at physiological serum concentrations, although 
at very high blood levels some maternal-fetal transfer may 
r 
occur. However, Keynes (67) reports that administration of 
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500 jig daily to a pregnant woman on PTU did not prevent 
PTU goiter development in the infant. Carr at al (68), after 
giving approximately 1400 mg dessicated thyroid daily to a 
pregnant woman observed cord blood BEI of only 4.5 yg% in the 
fetus, who was shown to have a small residual of hyperfunctioning 
thyroid tissue; 2-hour RAI uptake was TL and 24-hour uptake 
was 37o. In studies of the rat (43,60), guinea pig (46) and 
sheep (51) placental transfer of TSH is found to be insignificant. 
Dussault et al (51) have shown that in preliminary studies in 
■i q 1 “| o r 
which J I and )I-labeled TSH is injected into fetal and 
maternal sheep, respectively, placental TSII transfer does not 
occur. In humans, fetal pituitary and serum TSH concentrations 
increase markedly between 18 and 22 weeks of gestation from 
ve^ low to relatively high levels, while maternal TSH 
concentration is fairly stable and show no correlation with 
fetal values (102.) . The data suggests that the fetal pituitary- 
thyroid. axis seems to function nearly independently of the 
maternal system. 
Recently, Jorgensen and his coworkers (69) have 
synthesized biologically active thyroid hormone analogues 
(Figure 1), which are smaller molecules having increased 
lipid solubility and decreased thyroxine-protein binding in 
comparison to the iodothyronines (70). The synthesis of these 
compounds raises the possibility that alteration of molecular 
structure of thyroid hormone may facilitate placental transfer. 
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Of particular interest is a non-halogenated thyroid hormone 
analog, 3,5-dimethyl-3'-isopropyl-L-thyronine known as DIMIT. 
DIMIT is approximately 20% as active as in the adult rat 
antigoiter assay (69,71). In addition, two other thyroid 
hormone analogues were evaluated; 3,5-diiodo-3'-isopropyl- 
L-thyronine abbreviated DIIIT and 3,5-diiodo-3'-secondary butyl- 
L-thyronine or DISBT. Both compounds have similar properties 
compared to DIMIT, except they are 15 times more active in the 
adult rat antigoiter assay and are slightly heavier molecules (70). 
It Is known that early diagnosis and treatment are 
important in minimizing central nervous system damage in newborn 
infants with hypothyroidism (6,72). When hypothyroid children 
are treated prior to three months of age, they attain 
significantly higher IQ's in comparison to infants who are 
administered thyroid hormones at four months or older (6). It 
is not clear to what extent brain growth and development are 
dependent on thyroid hormone in utero. A critical period 
certainly exists, during which normal central nervous system 
development is dependent on the presence of thyroid hormone (6, 
7,72-24). This period has been shown to occur postnatally in 
the rat (7,74), but in man and other species in which the 
central nervous system is more mature at birth, this critical 
time presumably begins in utero (7). Whether subsequent 
administration of thyroid hormones can correct abnormalities 
due to intrauterine lack of thyroid hormones is not known. 
In the rat, hypothyroidism induces skeletal and cerebellar 
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abnormalities which are only prevented if is given 
during the first two postnatal weeks (74,75). In species 
with a more differentiated central nervous system at birth, 
thyroxine administered within three months after birth may 
not correct prenatal abnormalities created by the lack of 
thyroid hormone during gestation (8,72,73). In the ovine 
fetus thyroidectomized in utero, clinical rnanisfestations of 
hypothyroidism are most apparent in the skin, bone, and nervous 
system. Findings include a low body weight, shortened limbs, 
and retarded maturation and growth of wool follicles and 
osseous tissue (76,77). Athyreotic lambs exhibit no inclination 
to suck despite assistance, perhaps indicative of retarded 
brain development (76). In addition, thyroid deprivation is 
found to cause myelin fragmentation and a decrease in 
cerebellar intra-cytoplasmic vesicles and synapses in neonatal 
cretin lambs (77). There are some recent observations in 
fetal sheep suggesting that intrauterine hypothyroidism does 
not impair brain growth and only minimally delays ruyelination (78). 
Clinically, combined maternal-fetal hypothyroidism 
in the rhesus monkey results in marked retardation of skeletal 
growth and maturation and the recognizable clinical syndrome 
of cretinism (80). Radioiodine-treated rhesus monkeys have 
a 20% decrease in CNS protein and RNA synthesis and ganglioside 
deposition (79). The data indicates that in the absence of 
thyroid hormone both neuronal and neuroglial cell populations 
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are functionally affected in the cerebrum and cerebellum (79). 
Rhesus monkeys are shown to be comparable to humans in terms 
of placental structure, morphological thyroid development, 
serum protein species transporting thyroid hormone, and the 
thyroidal and blood hormone iodine levels (81,82). 
Early clinical recognition of human cretins is 
difficult. Some athyreotic infants do manifest signs and 
symptoms of hypothyroidism in the newborn period (83). 
Characteristics of congenital hypothyroidism include 
prolonged gestation, large birth weights (>4 kg), protracted 
icterus, edema, abdominal distension, vomiting, and poor feeding. 
Other, less common findings, include hypothermia (<95 F), lag 
in stooling, large posterior fontanel, respiratory distress, 
peripheral cyanosis, and hypoactivity or lethargy. Radiologically, 
osseous retardation and epiphyseal dysgenesis are diagnostic (84-86) 
Smith et al (72) studied 128 cases of hypothyroidism and found 
that in eight of 15 patients diagnosed as severe cretins, and 
adequately treated by four months of age, the mean IQ was <90- 
In five of these patients, osseous development is noted to be less 
than an eight month fetal level, IQ attained in this group ranges 
from 28 to 68 with a mean of 52. In an additional six cases 
with osseous development of eight month fetal level or greater, 
the IQ ranges from 80 to 111 with a mean of 93. This data 
suggests that "...intrauterine hypothyroidism can exist, and 
the greater the extent of the intrautering hypothyroidism, as 
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evidenced by osseous retardation and epiphysial dysgenesis, 
the poorer is the mental prognosis in severe cretins even 
though adequately treated by four months of age (72)." Klein 
et al (6), shows that when hypothyroid infants are treated 
before the age of three months, 85% have an IQ above 85, whereas 
when treatment is delayed three to seven months, 85% have 
definitive mental deficiency. However, even when replacement 
therapy is initiated shortly after birth, the congenital cretin 
may remain clumsy, poorly coordinated and handicapped by 
speech problems (77). 
Should hypothyroidism in utero be diagnosed, the 
most appropriate mode of therapy has not been resolved, 
assuming maternal thyroid hormone is not readily accessible 
to the fetus. As evidence indicates that placental transfer 
of or is limited and erratic, the administration of 
massive doses of or to the mother would be relatively 
ineffective,with the additional risk of maternal thyrotoxicity, 
Van Herle et al (16) have attempted to treat a fetus exposed 
to radioactive iodide with four biweekly intramuscular 
injections of L-thyroxine (120 yg T^) in utero, beginning at 
32 weeks of gestation. During the 24th week, the mother was 
begun on oral doses of L-triiodothyronine (100 yg T^) daily. 
However, despite therapy, the patient was hypothyroid at birth 
with cord blood levels of and undetectable and TS1I 
markedly elevated. In contrast, the maternal serum 
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concentration was normal and a marked fetal to maternal 
TSH gradient was present, implying that the placenta is 
impermeable to and TSH. It was noted that an adequate 
dose would be difficult to supply via intramuscular 
in utero injections, as the fetus would require approximately 
350 yg/week of based upon daily iodothyronine turnover 
in the newborn and equal to 18 yg/kg/day (93), Intra- 
amniotic injections of have been suggested (40). Thyroid 
hormone injected into amniotic. fluid in the sheep is 
quantitatively absorbed by the fetus within 24 hours (87). 
However, the proper dose of thyroid hormone would be difficult 
to determine. This is crucial as acceleration of events in 
the brain due to hyperthyroidism can be just as disrupting 
as deceleration due to hypothyroidism (88). Even a temporary 
state of hyperthyroidism or hypothyroidism may interfere 
with normal brain development. A. number of events 
occurring in the brain are known to be dependent on thyroid 
hormone. In fatty acid metabolism, chain elongation of 
fatty acids is thyroid-dependent, while thyroid hormone 
is not necessary for the development of polyunsaturates (88). 
If a delay caused by the lack of thyroid hormone or 
acceleration due to an excess of thyroid hormone occurs, 
normal interrelationships are disrupted. This leads to 
disordered timing of maturation, causing asynchronous 
development (98). Nicholson and Altman (99) show that 
disturbed timing of cellular proliferation in the brain 
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of hypothyroid or hyperthyroid rats is associated with 
alterations in the number and type of cells present in the 
cerebellar cortex. In hypothyroidism, smaller, more tightly 
packed and less differentiated cells are, in part, responsible 
for a decreased weight of adult rat cerebrum and cerebellum. 
While in hyperthyroidism, the cerebral and cerebellar weight 
deficits are attributed to a permanent decrease in total cell 
number due to early differentiation and associated termination 
of cell proliferation (99). The number of arborations 
between neurons in the brain may also be reduced in 
hypothyroidism (88). Eayrs (100) shows that hypothyroid 
rats demonstrate perseveration, and feels this may be due 
to the decreased arboration and neuron-neuron interaction. 
Mongoloid children, with decreased arboration in the brain, 
show a decreased variability in the amplitude of electrical 
potentials in EEC tracings, which can also be shown in 
hpothyroid children (88). In the cerebellum of hyperthyroid 
rats, the external granular layer disappears earlier and 
DNA synthesis stops earlier (99). These changes in humans 
early in life are associated with an accelerated functional 
development, but, in adulthood are associated with 
decreased functional ability (89). Changes in'fetal thyroid 
hormone status may cause alterations of the developing 
central nervous system in utero. 
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The current study was undertaken to investigate 
the possible role of thyroid hormone analogues in the 
treatment of in utero hypothyroidism. 
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MATERIAL AND METHODS 
Pregnant Sprague-Dawley rats were obtained on 
day ten post-coitus from Charles Dawson Laboratories. The 
animals were kept in a controlled environment with a constant 
temperature of 75-80° F. and with lighting from 7:00 a.m. 
until 7:00 p.m. The animals were given access to food and 
water ad libitum for five days prior to beginning the experiment. 
The pregnant rats were then divided randomly into groups. 
The control group was given ground Purina Laboratory Chow 
(containing 1.7 ppm iodine); while the experimental groups 
were given 0.3% propylthiouracil (PTU) in ground Purina 
Laboratory Chow from day 16 of gestation to induce fetal 
goitrogenesis (43,45,58). (Figure 2) At the same time, 
0.5 ml. daily intramuscular injections of either T^, T^ or 
the thyroid hormone analogues dissolved in ethanol were begun. 
The control group and the PTU-diet control group were injected 
with 0.5 ml. of pure ethanol. 
Food intake was measured daily. Since the groups 
on the 0.3%, PTU-diet did not consume as much as the control 
group, food intake of the former groups was averaged and this 
mean intake was given to the group on a normal diet. 
The dose of thyroxine was based on data suggesting 
that a euthyroid replacement dose of T^ in thyroidectomized 
rats is 1.3 Pg per 100 gram body weight per day (43,44,90-92). 
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Doses of thyroid hormones and analogues were calculated as 
Vig per 100 gram maternal body weight in pregnant rats. 
Weights ranged from 200 to 300 grams by day 16 of gestation. 
Daily IM injections were alternated in both thighs for five 
days prior to sacrifice (Figure 2). Solutions of the thyroid 
hormones and analogues were kept refrigerated and used over a 
two week period. 
Rats were sacrificed by exsanguination under 
ether anesthesia on day 21 of gestation. Maternal blood was 
obtained from the inferior vena cava. Following hysterotomy, 
the fetuses were sacrificed and exsanguinated by decapitation; 
blood from fetuses of a single litter were pooled. With the 
use of a dissecting microscope, fetal thyroids were removed 
intact with the trachea. The thyroids were then separated 
from the trachea. Each thyroid was weighed on a torsion 
scale (45), and all thyroids of a’ single litter were pooled 
in ten percent formalin for histological staining. Several 
studies were done in a double blind fashion to judge the 
reliability of the weighing procedure. 
Maternal and fetal serum TSH concentrations were 
measured by radioimmune assay using ^^1. On the final day 
of each experiment, the maternal and fetal blood obtained 
was centrifuged and the serum placed in the freezer for 
subsequent assay. Fetal sera from one or two experiments were 
pooled to obtain a sufficient quantity for assay; separate 
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determinations of corresponding maternal serum TSH concentrations 
were done at the same time. TSH values of control and 
experimental groups injected with the same compound (T^, T^, 
DIMIT, DIIIT or DISBT) were then averaged. 
The Student T-test was utilized for determinations 
of the significance of differences between means. All values 




Initially, a series of experiments were done to 
determine doses of thyroid hormones and analogues which 
prevented PTU-induced fetal goiter. When pregnant rats 
were fed a 0.3% PTU-diet from day 16 to day 20 of gestation 
(Figure 2), mean fetal thyroid weight was found to be 
significantly increased compared to control thyroid weight. 
(Table 1, Figure 3) Control fetal thyroids weighed 1.10 ± 0.05 mg, 
while the mean fetal thyroid weight of PTU-fed rats was 
1.92 ± 0.11 mg (p < .0001). 5.2 yg of T^ (sodium L-thyroxine 
pentahydrate) per 100 gram maternal body weight from day 16 to 
dayT 20 were required to prevent the occurrence of fetal goiters 
in rats fed PTU. This dosage of T^ produced a mean fetal 
thyroid weight of 1.18 ± 0.07 mg. There was no suppression 
of fetal goiter with 2.56 yg T^: mean thyroid weight was 
1.68 ± 0.14 mg. However, 2.56 yg of T^ (sodium salt of triiodo- 
L-thyronine) per 100 gm maternal B.W. was sufficient to prevent 
goiter formation and resulted in a mean fetal thyroid weight 
of 1.27 ± 0.07 mg. When 1.28 yg of T^ was injected into rats 
fed PTU, fetal goiters were not inhibited; mean fetal thyroid 
weight was 1.77 ± 0.08 mg. In contrast, 0.45 yg of DIMIT 
(3,5-dimethyl-3'-isopropyl-L-thyronine) per 100 gm maternal B.W. 
prevented fetal, goiter formation. Mean fetal thyroid weight 
was 1.05 ± 0.05 mg. A dose of 0.23 yg of DIMIT did not 
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prevent fetal goiter with a mean fetal thyroid weight of 
1.76 ± 0.09 mg. 
The thyroid hormone analogues, 3,5-diiodo-3'- 
isopropyl-L-thyronine (DIIIT) and 3,5-diiodo-3'-secondary 
butyl-L-thyronine (DISBT), were also evaluated. Although, 
both of these compounds have 15 times more thyromimetic 
activity when compared to DIMIT in the adult rat antigoiter 
assay (70), they are larger molecules with increased protein 
binding to TBG (70). Both these characteristics may be 
associated with decreased placenta transfer. 
Control fetal thyroid weight was 1.15 ± 0.06 mg and 
the mean fetal thyroid weight of PTU-fed animals was 1.78 ± 
0.13 mg (p < .001). (Table 2, Figure 4) 0.45 yg of DIMIT 
per 100 gm maternal body weight daily administered to PTU-fed 
rats again prevented the development of fetal thyroid goiter; 
mean thyroid weight was 0.90 ± 0.07 mg, slightly less than 
mean control fetal thyroid weight. Fetal goiters were not 
prevented when 0.45 yg of DIIIT or 0.45 yg of DISBT was 
injected into rats fed PTU with mean fetal thyroid weights of 
1.78 ± 0.08 mg and 1.68 ± 0.09 mg, respectively. However, 
0.90 yg of these compounds did prevent fetal goitrogenesis 
with mean fetal thyroid weights of 1.05 ± 0.06 mg in PTU-fed 
rats injected with DIIIT and 1.01 ± 0.06 mg in rats given DISBT. 
There was no significant difference between DIMIT and these 
analogues in the prevention of goitrogenesis when calculated 
by molecular weight. 
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Histological examination of the fetal thyroids 
did not reveal objective differences between the various 
groups. Ingestion of PTU by the mother resulted in enlargement 
and some minimal disorganization of the follicular structure 
of the fetal thyroid glands. 
Mean pooled fetal TSH levels paralleled mean fetal 
thyroid weights. (Figure 5) Control fetal serum TSH was 
88 ng/ml (19 yU/ml) compared to 135 ng TSH/ml (30 PU TSH/ml) 
in fetuses exposed to PTU. When 0.45 or 0.90 yg of DIMIT 
per 100 gm maternal body weight was given with PTU, fetal 
serum TSH was not detectable. In animals injected with 
5.20 yg T^ , mean fetal serum TSH was about 1/3 control fetal 
TSH values (25 ng TSH/ml; 6 yU TSH/ml). Fetal serum TSH 
approximated control fetal TSH concentration (85 ng TSH/ml; 
19 yU TSH/ml) when 2.56 yg T^ was administered. When the 
thyroid hormone analogues, DIXIT arid DISBT were injected in 
doses of 0.90 yg per 100 gram maternal body weight daily, 
no TSH was detectable in fetal serum. 
Maternal serum TSH was 24 ng/ml (5 yU/ml) in control 
rats; a PTU-diet resulted in serum TSH increased to 89 ng/ml 
(20 yU/ml). (Figure 6) Although 5.20 yg T^ or 2.56 yg T^ per 
100 gram maternal body weight administered along with PTU 
suppressed maternal serum TSH to less than control maternal 
TSH concentration, 0.45 yg DIMIT failed to completely counteract 
the increase in maternal serum TSH due to the PTU. Rats 
treated with T^ or T^ has serum TSH levels of 15 ng/ml 
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(3 yU TSH/ml) and 475 ng/rnl (1 yU TSII/ml) , respectively. 
Maternal serum TSH in rats fed PTU and injected with 
0.45 yg DIMIT was 46 ng/ml (10 yU TSH/ml). Serum TSH 
concentration in rats exposed to twice the goiter preventing 
dose of DIMIT, or 0.09 yg, was 5 ng/ml (1 yU TSH/ml). When 
0.09 yg DIIIT per 100 gm maternal B.W. was administered to 
rats fed PTU, serum TSH was undetectable. Rats injected 
with 0.09 yg DISBT had 7.5 ng TSH/ml (2 yU TSH/ml). 
Since the thyroid hormone analog DIMIT is not a 
natural hormone, several experiments were done to determine 
possible teratogenic effects. Injections of 3.6 yg DIMIT per 
100 gm maternal body weight, or approximately eight times the 
dose of DIMIT which suppresses goiter formation were begun on 
the eighth day of gestation, after implantation of the embryo 
had occurred. Subsequent injections were given on alternate 
days. Control rats and experimental rats were sacrificed 
on day 12, day 16, and day 19 of gestation. No gross 
abnormalities could be found in the fetuses exposed to DIMIT 
in utero. However, two pregnant rats injected with the 
same amount of DIMIT and permitted to undergo natural delivery, 
ate the newborn rats, which might indicate that the fetuses 
were abnormal. Earlier experiments with very high doses of 
DIMIT, more than 30 times the dose of DIMIT inhibiting fetal 
goitrogenesis, administered to PTU-fed rats daily from day 16 
through day 20 of gestation, did produce fetuses that appeared 
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slightly erythematous and edematous in comparison to 
control fetuses. Weights of these fetuses did not 





In the present study, pregnant rats received 
propylthiouracil (PTU) in an attempt to produce fetal goiters. 
When these rats were given an 0.3% PTU-diet for the last 
five days of gestation, the mean absolute fetal thyroid 
weight approximately doubled compared to control fetal thyroid 
weight which is consistent with previous observations. 
Hamburgh et al (43) and Knobil and Josimovich (45) found that 
a maternal diet of 0. 17,-0.2% PTU throughout the last week or 
two weeks of gestation in pregnant rats, caused fetal goiters 
which were twice as large as thyroids of control fetuses. 
Hoskins, Van Arsdel and Williams (58) reported that newborn 
offspring of mothers who had received 1% PTU from the 
beginning of gestation (22-23 da}^), had thyroids that weighed 
approximately five times control newborn thyroid weight. Since 
Maternal thyroidectomy or hypophysectomy did not affect fetal 
thyroid weight, they calculated that goiter formation in the 
fetus following a PTU-diet in pregnant rats was mediated by 
the fetal-pituitary axis (45) . 
Pharmocologic doses of thyroxine (T^) and triiodothyronine 
(T^) had to be administered to the pregnant rat on a PTU-diet in 
order to prevent fetal goitrogenesis. 5.20 yg T^ or 2.56 yg T^ 
per 100 gram maternal body weight daily were necessary. The 
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physiologic replacement dose of in rats has been shown 
to be 1.3 yg per 100 gram body weight (90,91). Cullen, 
Doherty and Ingbar (92) showed that 6.7 yg of or 
2.2 yg of per 100 gram body weight caused thyrotoxicosis 
in rats. The previous data suggested that the large doses 
of iodothyronin.es required to cross the placenta and prevent 
fetal goiter formation due to a maternal diet of PTU would 
cause thyrotoxicity in the pregnant mother. 
Hamburgh et al (43) found that at least 50 yg 
(free acid base of L-thyroxine) per day from day 15 of 
geatation was necessary to inhibit fetal goiter due to 
maternal ingestion of 0.2% PTU. 25 yg T^ daily did not 
appreciably inhibit fetal goitrogenesis. In the study by 
Knobil and Josimovich (45), 15 yg T^ (sodium salt of L-thyroxine) 
or the same amount of T^ daily was sufficient to prevent fetal 
goiter due to a maternal diet of 0.17o PTU from day 11 of 
gestation, Hoskins, Van A?rsdel and Williams (58) noted that 
newborn rats of animals on 1% PTU that were injected with 
100 yg T^ (sodium L-thyroxine pentahydrate) every 12 hours 
throughout gestation had thyroid weights equal to control 
thyroid weight. 
Results of maternal and fetal serum TSH concentrations 
correlated well with the activity of the thyroid hormones 
and analogues as determined by fetal thyroid weight. As 
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expected, a PTU diet significantly increased both maternal 
and fetal serum TSII. When ovine fetuses were thyroidectomized 
in utero, serum TSH was significantly elevated at birth (63). 
It should also be noted that significant thyroid enlargement 
in fetuses of thyroidectomized or hypophysectomized rats and 
guinea pigs treated with PTU, occurred only when the fetal 
hypophysis was intact (30,45). In humans, treatment with 
PTU, during gestation, caused elevation of serum TSH in 
affected offspring (27). The hypothyroid newborn of a 
mother exposed to radioiodine during gestation, had 
significantly elevated levels of cord blood TSH compared to 
the TSH concentrations in cord blood of euthyroid newborns (16). 
It is clear that, in man as in animals, PTU can produce fetal 
goiter and that the athyreotic fetus manifested low T^ and Tq 
concentrations and increased serum TSH in cord blood (16,27,63,77). 
In the present study, the mean serum TSH values in 
mothers who had received goiter preventing doses of the 
iodothyronines were equal to the mean serum TSH in the control 
group. In the fetuses of the T^ and T^ injected mothers, 
serum TSH levels were less than or equal to control fetal TSH. 
When 0.45 yg of DIMIT was administered to pregnant rats fed 
PTU, maternal TSH concentration fell between control maternal 
serum TSH level and maternal serum TSH of rats fed PTU; yet, 
in the fetuses of DIMIT-injected rats no TSH was detected. 
DIIIT completely suppressed maternal TSH; while animals treated 
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with DISBT and fed PTU had a serum TSH concentration that 
was less than 1/3 control maternal serum TSH. Fetal serum 
TSH levels of animals injected with D1IIT or DISBT were 
undetectable. The data implied that while DIMIT crossed the 
placenta and prevented fetal goitrogenesis, the concentration 
in the mother was not high enough to suppress TSH. 
Which of these properties - molecular weight, lipid 
solubility, or protein binding is most important in increasing 
placental transfer remains to be determined. (Figure 7) DIMIT 
is the smallest of the three analogues and therefore should 
cross the placenta more easily. All three compounds have 
increased lipid solubility in comparison to T^ (70), which 
should enhance placental permeability. The addition of iodide 
to DIIIT and DISBT should increase lipid solubility because 
iodide is two and a half times as lipophilic as a methyl group 
on DIMIT. However, this increased lipid solubility is offset 
by heightened protein binding secondary to increased 
ionization of the phenolic hydroxy (OH) group on the 3-ring 
caused by the addition of iodide. In addition, DIMIT does not 
bind to TBG as well as the other analogues (70). This would 
allow an increased amount of unbound hormone to be available 
for placental transfer. 
Another factor that must be considered is the 
possibility that the iodinated thyroid hormone analogues, 
DIIIT an DISBT, may be acted upon by the fetal a-ring 
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deiodinase, which forms the inactive reverse (101), 
whereas DIMIT lacks the iodide necessary for such a reaction. 
Finally, if the dose of thyroid hormone which 
prevents fetal goiter is so large that it causes maternal 
thyrotoxicosis, clinical benefit would be marginal. Therefore, 
the relationship between, the effect of thyroid hormone on 
the fetus and the effect of thyroid hormone on the mother is 
very significant. In Figure 8, the numbers are all relative 
to the activity of thyroxine (T^). The numbers in the first 
column compare the activity of T^ and the thyroid hormone 
analogues to the activity of T^ in the mother in terms of moles (70) 
The numbers in the second column compare the molar activity 
of T^ and the thyroid hormone analogues to the dose of T^ in 
moles required to block fetal goiter. As is shown, DIMIT is 
only 20% as active as T^ (69); yet, it has four and a half 
times the activity of T, in the fetus, presumably secondary to 
its increased placental permeability. The other two 
analogues, DIIIT and DISBT, are three times as active as T^ in 
the mother; and are a little more than three and a half times 
as active as T^ in the fetus. Therefore, DIMIT has an effect 
in the fetus compared to an effect on the mother that is more 
than 20 times that of T,. In comparison, DIIIT and DISBT have 
an effect that is less than one and a half times that of T^. 
The data indicates that the amount of non-halogenated thyroid 
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hormone analog, DIMIT, preventing fetal goiter would not 
increase maternal thyroid hormone activity significantly. 
Thyroid hormone analogues like DIMIT may have 




1. Doses of thyroxine (T^) and triiodothyronine (T^) which 
prevented fetal goiter would cause maternal thyrotoxicosis. 
2. The non~halogenated thyroid hormone analog, 3,5-dirnethyl- 
3'-isopropyl-L-thyronine (DIMIT), prevented fetal goiter 
at a maternal dose that had little thyromimetic activity. 
3. The data indicated that thyroid hormone analogues with 
smaller molecular weight, increased lipid solubility, and 
decreased binding to TBG crossed the placenta more easily 
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GROUP DIET DOSE 
lOOgro/B.W./day 




I NORMAL - 1.10 ± 0.05 - pc.0001 
II PTU - 1.92 ± 0.12 p<.0001 - 
III PTU 5.20 P g 1.18 ± 0.07 N.S . pc.001 
IV PTU 2.60 V& T4 1.68 ± 0.14 pc.001 N.S. 
V PTU 2.56 yg t3 1.27 ± 0.07 N.S . pc.001 
VI PTU 1.28 yg t3 1.77 ± 0.08 p<.0001 N.S . 
VII PTU 0.45 yg DIMIT 1.05 ± 0.05 N.S . pc.0001 
VIII PTU 0.23 yg DIMIT 1.76 ± 0.09 p < . 0 0 01 N.S . 
ALL VALUES ARE ± S . E . M. 
ONE OR TWO LITTERS (5-13 FETUSES/LITTER) 
"''represents comparison between experimental animals given T, , T~ OR 






























O ^ - 
K ° ? 







4J 0 • 
43 co 
b£)4-l P 
•H O CO 
0) P 
ex! £ 4J 4-J 
C5» 
H 43 P 
•'<. /—\ 13 60 CP 
CD r« COrl 
S?" H O P r*3 
d 
o 5-4 £ rH 
0) 43 13 o 
©> p 4J *H -p 
•H o 
P r-l P cn 
CO tu=k O exs 
CvJ p P 43 co 
„* a) 4-) C3 
43 «4-4 •H 
C3» 
4-1 rH Cd 
o p Cd *U 
13 O P P 
O 0) O 
If) !*= *H /—s cp a 
« •i-l H 
CC5 P !—! P P 








O p t—i 
CO £■—■! txO vC< 
cJ ^ o 4J 43 
1-i a 
P P co cd 
©> p p P M 
3L •p p P 
o H X 
P 
C\i O P co * 
if) p p P CO 
rP O p p 
,c B Pu P 
4-1 P P 4-J 
a P 44 
LP 43 
o P rP 
13 P 
P *H 43 O 
y o J5 
p p 43 P 
*4-1 f>^ O 
CP 43 cd p 











GROUP DIET DOSE 
lOOgm/B.W./day 




I NORMAL - 1.15 ±0.06 - p<.001 
II PTU - 1.78 ± 0.13 p<.001 - 
III PTU 0.45 yg DIMIT 0.90 ± 0.07 p< . 05 p<.001 
IV PTU 0.45 jig DIIIT 1.78 ± 0.08 p<.0001 N. S . 
V PTU 0.90 yg DIIIT 1.05 ± 0.06 N. S . p< . 0001 
VI PTU 0.45 yg DISBT 1.68 ± 0.09 p<.0001 N.S . 
VII PTU 0.90 yg DISBT 1.01 ± 0.06 N. S . p<.0001 
ALL VALUES ARE ±S.E.M. 
"ONE OR TOO LITTERS (5-13 FETUSES/LITTER) 
^"REPRESENTS COMPARISON BETWEEN EXPERIMENTAL ANIMALS GIVEN DIMIT, 
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